论文部分内容阅读
目的 研究第三代头孢类抗菌药物治疗肺癌术后感染患者的临床效果,探讨对炎性应激状态的影响。方法 选取2015年1月-2016年12月收治的88例肺癌术后感染患者,随机分为试验组及对照组,每组44例;试验组患者静脉滴注头孢哌酮舒巴坦钠,对照组患者静脉滴注头孢呋辛;观察并记录两组患者症状改变情况及不良反应发生情况及术后1d、3d临床指标。结果 试验组的有效率为88.64%,高于对照组的70.45%(P<0.05);与对照组比较,试验组的发热、痰中带血、咳嗽及肺部啰音或实变等症状改善时间均缩短(P<0.05);试验组术后并发症及不良反应发生率为4.55%,低于对照组的20.45%(P<0.05);在术后1d、3d时与对照组比较,试验组的IL-1、TNF-α、PCT及CRP表达水平均降低(P<0.05),IL-4、IL-10表达水平均升高(P<0.05)。结论 第三代头孢类抗菌药物对肺癌术后感染患者有较好的临床效果,能够抑制患者炎性应激状态,有效改善患者症状,不良反应发生率较低。
Objective To study the clinical effect of the third generation cephalosporin antimicrobial agents in the treatment of patients with postoperative lung cancer infection and to explore the impact on inflammatory state. Methods Eighty-eight patients with postoperative lung cancer who were admitted to our hospital from January 2015 to December 2016 were randomly divided into test group and control group, with 44 patients in each group. Patients in the test group were given cefoperazone sulbactam sodium intravenously, Group patients were given intravenous cefuroxime. The changes of symptoms and adverse reactions in both groups were observed and recorded. The clinical indexes of postoperative 1d and 3d were observed and recorded. Results The effective rate of the experimental group was 88.64%, which was higher than that of the control group (70.45%) (P <0.05). Compared with the control group, the experimental group had improved fever, bloody sputum, cough and pulmonary rales or consolidation (P <0.05). The incidence of postoperative complications and adverse reactions in the experimental group was 4.55%, which was lower than that in the control group (20.45%, P <0.05). Compared with the control group at 1 and 3 days after operation, The levels of IL-1, TNF-α, PCT and CRP were decreased (P <0.05), while the levels of IL-4 and IL-10 were increased (P <0.05). Conclusion The third-generation cephalosporin antimicrobial agents have a good clinical effect on patients with postoperative lung cancer infection, which can inhibit inflammatory state and improve the symptoms of patients with low incidence of adverse reactions.